Essity (ESSITY) CMD 2024 summary

Strategic Vision and Financial Targets

• Aims to be the undisputed global leader in hygiene and health, targeting annual organic sales growth above 3% and EBITDA/EBITA margin above 15%, with a focus on profitable growth and shareholder value creation.

• Growth strategy centers on expanding in high-margin categories and leveraging strong market positions in Health & Medical, Consumer Goods, and Professional Hygiene.

• Capital allocation prioritizes organic capex, targeted M&A, stable and rising dividends, recurring share buybacks, and maintaining a solid investment grade balance sheet.

• Efficiency, innovation-driven mix, and portfolio optimization are key levers for margin expansion and value creation.

• Growth pillars include nurturing core categories, expanding for more, and exploring new opportunities, with a focus on efficiency and innovation.

Market Trends and Growth Drivers

• Rising disposable incomes, aging populations, increased chronic conditions, and well-being awareness drive global category growth.

• Geographic exposure to markets growing 2-4% CAGR, with higher growth in Asia and emerging markets.

• Health & Medical targets above-market growth, leveraging leadership in incontinence, wound care, and compression therapy.

• Consumer Goods focuses on high-margin segments like incontinence and feminine care, with strong expansion in the U.S. and Latin America.

• Professional Hygiene prioritizes premium, strategic systems and digital solutions, aiming for growth above 2% and market leadership.

Operational Excellence, Innovation, and Sustainability

• End-to-end, customer-centric supply chain supports margin expansion and growth, with a focus on safety, quality, and agility.

• Investments in digitalization, automation, and advanced planning enable lean operations and rapid response to market changes.

• Sustainability initiatives include significant reductions in Scope 1, 2, and 3 emissions, renewable energy adoption, and breakthrough technologies like waterless tissue production; science-based targets validated by SBTi.

• Supply chain resilience demonstrated by uninterrupted deliveries during COVID and global disruptions.

• Annual COGS savings of SEK 0.5–1bn targeted through supply chain optimization and digitalization.